BEACON: A Summary Framework to Overcome Potential Reimbursement Hurdles
Author
Abstract
Suggested Citation
DOI: 10.1007/s40273-016-0427-7
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
References listed on IDEAS
- P. Thokala & A. Duenas, 2012. "Multiple Criteria Decision Analysis for Health Technology Assessment," Post-Print hal-00800398, HAL.
- Valérie Paris & Annalisa Belloni, 2013. "Value in Pharmaceutical Pricing," OECD Health Working Papers 63, OECD Publishing.
- Office of Health Economics, 2015. "A Framework for Payer Assessment of the Value of New Technologies: A US Approach," Seminar Briefing 001589, Office of Health Economics.
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- Jonathan Dando & Maximilian Lebmeier, 2020. "A novel valuation model for medical intervention development based on progressive dynamic changes that integrates Health Technology Assessment outcomes with early-stage innovation and indication-speci," Journal of Innovation and Entrepreneurship, Springer, vol. 9(1), pages 1-28, December.
- Dunlop, William C.N. & Staufer, Alexandra & Levy, Pierre & Edwards, Guy J., 2018. "Innovative pharmaceutical pricing agreements in five European markets: A survey of stakeholder attitudes and experience," Health Policy, Elsevier, vol. 122(5), pages 528-532.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Claude Montmarquette & Stéphanie Boulenger & Joanne Castonguay, 2014. "Les risques liés à la création de PHARMA-QUEBEC," CIRANO Project Reports 2014rp-05, CIRANO.
- Fernando Antoñanzas & Robert Terkola & Maarten Postma, 2016. "The Value of Medicines: A Crucial but Vague Concept," PharmacoEconomics, Springer, vol. 34(12), pages 1227-1239, December.
- Angelis, Aris & Kanavos, Panos, 2017. "Multiple Criteria Decision Analysis (MCDA) for evaluating new medicines in Health Technology Assessment and beyond: The Advance Value Framework," Social Science & Medicine, Elsevier, vol. 188(C), pages 137-156.
- Wettstein, Dominik J. & Boes, Stefan, 2022. "How value-based policy interventions influence price negotiations for new medicines: An experimental approach and initial evidence," Health Policy, Elsevier, vol. 126(2), pages 112-121.
- Barbara Bini & Milena Vainieri & Sabina Nuti, 2015. "Definizione delle priorit? di intervento in sanit?: approcci socio-tecnici a confronto," MECOSAN, FrancoAngeli Editore, vol. 2015(93), pages 49-73.
- Melanie Büssgen & Tom Stargardt, 2023. "10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?," Applied Health Economics and Health Policy, Springer, vol. 21(5), pages 751-759, September.
- Henk Broekhuizen & Maarten J. IJzerman & A. Brett Hauber & Catharina G. M. Groothuis-Oudshoorn, 2017. "Weighing Clinical Evidence Using Patient Preferences: An Application of Probabilistic Multi-Criteria Decision Analysis," PharmacoEconomics, Springer, vol. 35(3), pages 259-269, March.
- Bernhard Ultsch & Oliver Damm & Philippe Beutels & Joke Bilcke & Bernd Brüggenjürgen & Andreas Gerber-Grote & Wolfgang Greiner & Germaine Hanquet & Raymond Hutubessy & Mark Jit & Mirjam Knol & Rüdiger, 2016.
"Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community,"
PharmacoEconomics, Springer, vol. 34(3), pages 227-244, March.
- Bernhard Ultsch & Oliver Damm & Philippe Beutels & Joke Bilcke & Bernd Brüggenjürgen & Andreas Gerber-Grote & Wolfgang Greiner & Germaine Hanquet & Raymond Hutubessy & Mark Jit & Mirjam Knol & Rüdiger, 2016. "Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community," PharmacoEconomics, Springer, vol. 34(3), pages 227-244, March.
- Sabine Vogler & Valérie Paris & Alessandra Ferrario & Veronika J. Wirtz & Kees Joncheere & Peter Schneider & Hanne Bak Pedersen & Guillaume Dedet & Zaheer-Ud-Din Babar, 2017. "How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries," Applied Health Economics and Health Policy, Springer, vol. 15(3), pages 307-321, June.
- Sun-Hong Kwon & Hea-Sun Park & Young-Jin Na & Chul Park & Ju-Young Shin & Hye-Lin Kim, 2021. "Price Reduction of Anticancer Drugs from 2007 to 2019 in South Korea: The Impact of Pharmaceutical Cost-Containment Policies," Applied Health Economics and Health Policy, Springer, vol. 19(3), pages 439-450, May.
- Mónica D. Oliveira & Inês Mataloto & Panos Kanavos, 2019.
"Multi-criteria decision analysis for health technology assessment: addressing methodological challenges to improve the state of the art,"
The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(6), pages 891-918, August.
- Oliveira, Mónica D. & Mataloto, Inês & Kanavos, Panos, 2019. "Multi-criteria decision analysis for health technology assessment: addressing methodological challenges to improve the state of the art," LSE Research Online Documents on Economics 100763, London School of Economics and Political Science, LSE Library.
- Aris Angelis & Panos Kanavos, 2016. "Value-Based Assessment of New Medical Technologies: Towards a Robust Methodological Framework for the Application of Multiple Criteria Decision Analysis in the Context of Health Technology Assessment," PharmacoEconomics, Springer, vol. 34(5), pages 435-446, May.
- Rotar, Alexandru M. & Preda, Alin & Löblová, Olga & Benkovic, Vanesa & Zawodnik, Szymon & Gulacsi, Laszlo & Niewada, Maciej & Boncz, Imre & Petrova, Guenka & Dimitrova, Maria & Klazinga, Niek, 2018. "Rationalizing the introduction and use of pharmaceutical products: The role of managed entry agreements in Central and Eastern European countries," Health Policy, Elsevier, vol. 122(3), pages 230-236.
- Axel C. Mühlbacher & John F. P. Bridges & Susanne Bethge & Ch.-Markos Dintsios & Anja Schwalm & Andreas Gerber-Grote & Matthias Nübling, 2017. "Preferences for antiviral therapy of chronic hepatitis C: a discrete choice experiment," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(2), pages 155-165, March.
- Carlos Campillo-Artero & Jaume Puig-Junoy & Anthony J. Culyer, 2018. "Does MCDA Trump CEA?," Applied Health Economics and Health Policy, Springer, vol. 16(2), pages 147-151, April.
- Vogler, Sabine & Zimmermann, Nina & de Joncheere, Kees, 2016. "Policy interventions related to medicines: Survey of measures taken in European countries during 2010–2015," Health Policy, Elsevier, vol. 120(12), pages 1363-1377.
- Ariel Beresniak & Antonieta Medina-Lara & Jean Auray & Alain Wever & Jean-Claude Praet & Rosanna Tarricone & Aleksandra Torbica & Danielle Dupont & Michel Lamure & Gerard Duru, 2015. "Validation of the Underlying Assumptions of the Quality-Adjusted Life-Years Outcome: Results from the ECHOUTCOME European Project," PharmacoEconomics, Springer, vol. 33(1), pages 61-69, January.
- Chisholm, Orin & Sharry, Patrick & Phillips, Lawrence, 2022. "Multi-criteria decision analysis for benefit-risk analysis by national regulatory authorities," LSE Research Online Documents on Economics 114407, London School of Economics and Political Science, LSE Library.
- Maynou, Laia & Cairns, John, 2019. "What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries," Health Policy, Elsevier, vol. 123(2), pages 130-139.
- López-Bastida, J. & Ramos-Goñi, J.M. & Aranda-Reneo, I. & Trapero-Bertran, M. & Kanavos, P. & Rodriguez Martin, B., 2019. "Using a stated preference discrete choice experiment to assess societal value from the perspective of decision-makers in Europe. Does it work for rare diseases?," Health Policy, Elsevier, vol. 123(2), pages 152-158.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:34:y:2016:i:10:d:10.1007_s40273-016-0427-7. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.